Outcomes of patients with up to 6 years of follow-up from a phase 2 study of idelalisib for relapsed indolent lymphomas

Nina D. Wagner-Johnston, Stephen J. Schuster, Sven deVos, Gilles Salles, Wojciech J. Jurczak, Christopher R. Flowers, Andreas Viardot, Ian W. Flinn, Peter Martin, Guan Xing, Nishanthan Rajakumaraswamy, Ajay K. Gopal

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'Outcomes of patients with up to 6 years of follow-up from a phase 2 study of idelalisib for relapsed indolent lymphomas'. Together they form a unique fingerprint.

Medicine & Life Sciences